Market Overview

Focus On Abbott Labs Remains On Pending Deals

Share:

Qualifying the second quarter results of Abbott Laboratories (NYSE: ABT) as solid, UBS indicated the focus of investors is now on the pending deals with Alere Inc (NYSE: ALR) and St. Jude Medical, Inc. (NYSE: STJ). Investors seek clarity on whether and when these deals will be consummated.

UBS Medical Supplies analyst Matt Miksic believes the Alere deal could have been done without, although opining that it would be incrementally positive. Over time, the analyst sees the St. Jude deal as presenting significant opportunity to create shareholder value. The timing, according to the analyst, is the critical element.

UBS noted the company is targeting a year-end close for the St. Jude deal. Among the catalysts that determine the success of the deal, UBS mentions 1) MRI safe label approvals, expected 2H16 for pacer leads and 1H17 for ICDs and 2) Progress on the NCD for CardioMEMS.

The firm also believes Abbott's solid showing in the Medical Devices and Diagnostics business bodes well for the second quarter Medical Devices trends. Among the other segments, which fared well on an underlying basis, was OUS businesses like established pharma. UBS noted that pediatric nutrition underperformed relative to its estimates.

Given the uncertainty surrounding the deals, UBS remains Neutral on Abbott. However, the firm is incrementally positive on Abbott's long-term prospects post the completion of the St. Jude deal. The firm believes the potential long-term benefits of the St. Jude deal may be offset by the uncertainties over the timing, execution and integration of the pending deals and adverse forex impact.

Full ratings data available on Benzinga Pro.

Latest Ratings for ABT

DateFirmActionFromTo
Nov 2020Morgan StanleyMaintainsOverweight
Oct 2020Credit SuisseMaintainsOutperform
Oct 2020JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!

Posted-In: Matt Miksic UBSAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
DISCitigroupMaintains175.0
AYLANoble Capital MarketsInitiates Coverage On29.0
SHOPSusquehannaInitiates Coverage On950.0
SICraig-HallumInitiates Coverage On50.0
WORKStephens & Co.Downgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com